Tourette syndrome, a neurodevelopmental disorder of motor and phonic tics, has long relied on behavioral therapy first-line and, when medication is needed, on dopamine D2-blocking antipsychotics with their attendant metabolic and movement side effects. The most significant recent development is a new pharmacologic class reaching the finish line of Phase 3.
Ecopipam: a first-in-class option nearing approval
Ecopipam is a selective dopamine D1 receptor antagonist — a mechanism distinct from the D2 antagonists used for decades. Its Phase 2b D1AMOND trial in children and adolescents showed a significant reduction in tic severity on the Yale Global Tic Severity Scale (roughly a 30% reduction from baseline; p=0.01), notably without the weight gain, metabolic changes, or drug-induced movement disorders typical of D2 antipsychotics.
The key update is that the confirmatory Phase 3 trial (an enriched-enrollment randomized-withdrawal design across pediatric and adult patients) met its primary and secondary endpoints: continued ecopipam roughly halved the risk of relapse versus placebo (hazard ratio ~0.5 in both the pediatric subgroup and the overall cohort). Common adverse events were somnolence, insomnia, anxiety, fatigue, and headache. A regulatory submission is planned; if approved, ecopipam would be the first genuinely new class of medicine for Tourette syndrome in over half a century.
Other approaches
Cannabinoid-based therapies (THC/CBD) have shown mixed results in adults, with some meta-analytic signal for reduced tic severity and premonitory urges but small, heterogeneous studies limiting firm conclusions; dizziness, dry mouth, and transient cognitive effects are common. Deep brain stimulation is reserved for severe, medication-refractory disease, producing meaningful tic and quality-of-life improvement, though the optimal target (thalamus vs globus pallidus internus) is still debated and hardware-related complications occur. Comprehensive Behavioral Intervention for Tics (CBIT) remains a first-line, evidence-based therapy delivered effectively in person or via telehealth, with durable benefit and an excellent safety profile.
| Therapy | Type | Efficacy | Notes |
|---|---|---|---|
| Ecopipam | D1 receptor antagonist | Positive Phase 2b and Phase 3 (~50% relapse-risk reduction) | Potential first new class in >50 years |
| Cannabinoids (THC/CBD) | Endocannabinoid modulation | Mixed; some benefit | Small studies, variable dosing |
| Deep brain stimulation | Neuromodulation | Significant in refractory cases | Reserved for severe disease |
| CBIT | Behavioral therapy | Strong, durable | First-line |
Further reading: Ecopipam Phase 2b D1AMOND (Gilbert et al., Pediatrics 2023) and Phase 3 (Gilbert et al., JAMA Neurology 2026); CBIT (Piacentini et al., JAMA 2010); cannabis-based medicine meta-analysis (2024); DBS for Tourette review (Martino et al.).